Post by account_disabled on Dec 28, 2023 3:53:28 GMT
Avery low price for resale by Concordia. Consequently this allowed Actavis to remain the sole supplier of tablets in the UK and to prolong the high prices charged in the market during which the cost to the National Health Service NHS of purchasing the drug rose from per pack. The NHS was prejudiced in that it did not benefit from the price reduction that would have resulted from genuine competition from Concordia which had obtained marketing authorization for hydrocortisone mg tablets and would have been the first potential competitor of Actavis.
The CMAs officer in charge said the anticompetitive agreements in question could Country Email List cost the NHS by distorting competition and failing to reduce the cost of lifesaving medicines such as hydrocortisone tablets and argued that the agreements in this case were intended to keep Actavis as the sole supplier and in a position to dictate and prolong high prices. In December in a separate investigation by the Competition and Markets Authority Actavis was accused of overcharging the NHS resulting in a price increase over several years.
That situation occurred after Actavis introduced the innovative version of the drug meaning that the drug then became generic meaning it was no longer subject to price regulation. very active in the pharmaceutical sector. In February the CMA fined a number of pharmaceutical companies a total of million for anticompetitive agreements and conduct in relation to the supply of the antidepressant drug Paroxetine and in December the CMA fined Pfizer and Flynn Pharma nearly million pounds for overcharging the NHS for an antiepilepsy drug. There are also two other ongoing investigations in the pharmaceutical sector. Sursa LEXOLOGY Leave a reply Your email address will not be published. Mandatory fields are marked with Comment Name Email Site web Save my name email and website in this browser for the next.
The CMAs officer in charge said the anticompetitive agreements in question could Country Email List cost the NHS by distorting competition and failing to reduce the cost of lifesaving medicines such as hydrocortisone tablets and argued that the agreements in this case were intended to keep Actavis as the sole supplier and in a position to dictate and prolong high prices. In December in a separate investigation by the Competition and Markets Authority Actavis was accused of overcharging the NHS resulting in a price increase over several years.
That situation occurred after Actavis introduced the innovative version of the drug meaning that the drug then became generic meaning it was no longer subject to price regulation. very active in the pharmaceutical sector. In February the CMA fined a number of pharmaceutical companies a total of million for anticompetitive agreements and conduct in relation to the supply of the antidepressant drug Paroxetine and in December the CMA fined Pfizer and Flynn Pharma nearly million pounds for overcharging the NHS for an antiepilepsy drug. There are also two other ongoing investigations in the pharmaceutical sector. Sursa LEXOLOGY Leave a reply Your email address will not be published. Mandatory fields are marked with Comment Name Email Site web Save my name email and website in this browser for the next.